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IMPORTANCE Guidelines recommend corticosteroids in patients with IgA nephropathy and
persistent proteinuria, but the effects remain uncertain.
OBJECTIVE To evaluate the efficacy and safety of corticosteroids in patients with IgA
nephropathy at risk of progression.
DESIGN, SETTING, AND PARTICIPANTS The Therapeutic Evaluation of Steroids in IgA
Nephropathy Global (TESTING) study was amulticenter, double-blind, randomized clinical
trial designed to recruit 750 participants with IgA nephropathy (proteinuria greater than 1 g/d
and estimated glomerular filtration rate [eGFR] of 20 to 120mL/min/1.73 m2 after at least
3 months of blood pressure control with renin-angiotensin system blockade] and to provide
follow-up until 335 primary outcomes occurred.
INTERVENTIONS Patients were randomized 1:1 to oral methylprednisolone (0.6-0.8mg/kg/d;
maximum, 48mg/d) (n = 136) or matching placebo (n = 126) for 2 months, with subsequent
weaning over 4 to 6months.
MAIN OUTCOMES ANDMEASURES The primary composite outcomewas end-stage kidney
disease, death due to kidney failure, or a 40% decrease in eGFR. Predefined safety outcomes
were serious infection, new diabetes, gastrointestinal hemorrhage, fracture/osteonecrosis,
and cardiovascular events. Themean required follow-up was estimated to be 5 years.
RESULTS After randomization of 262 participants (mean age, 38.6 [SD, 11.1] years; 96 [37%]
women; eGFR, 59.4mL/min/1.73 m2; urine protein excretion, 2.40 g/d) and 2.1 years’ median
follow-up, recruitment was discontinued because of excess serious adverse events. Serious
events occurred in 20 participants (14.7%) in themethylprednisolone group vs 4 (3.2%) in
the placebo group (P = .001; risk difference, 11.5% [95% CI, 4.8%-18.2%]), mostly due to
excess serious infections (11 [8.1%] vs 0; risk difference, 8.1% [95% CI, 3.5%-13.9%];
P < .001), including 2 deaths. The primary renal outcome occurred in 8 participants (5.9%) in
themethylprednisolone group vs 20 (15.9%) in the placebo group (hazard ratio, 0.37 [95%
CI, 0.17-0.85]; risk difference, 10.0% [95% CI, 2.5%-17.9%]; P = .02).
CONCLUSIONS AND RELEVANCE Among patients with IgA nephropathy and proteinuria of
1 g/d or greater, oral methylprednisolone was associated with an increased risk of serious
adverse events, primarily infections. Although the results were consistent with potential renal
benefit, definitive conclusions about treatment benefit cannot bemade, owing to early
termination of the trial.
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Immunoglobulin A nephropathy is themost prevalent pri-mary glomerular disease, particularly in the Asia-Pacificregion.1 Up to 30%of all peoplewith IgAnephropathywill
eventually develop end-stage kidney disease (ESKD)2; de-
creased kidney function, persistent proteinuria, and hyper-
tension are the strongest risk factors.3,4
Theuseofrenin-angiotensinsystem(RAS)blockadehasbeen
shownto reduce the riskofkidney failure inpatientswithhigh-
risk IgA nephropathy5,6 and is thus guideline-recommended
therapy.7,8Despite this,a largeproportionof individualswill still
develop ESKD, so better treatments are required.
Although IgA nephropathy is an immune-complex–
mediated glomerulonephritis, the role of immunosuppres-
sion remains controversial.8Ameta-analysis of previous trials
suggested substantial benefitwith corticosteroid therapy, but
trialqualitywassuboptimal,most trialsweresingle-center, and
adverse outcomes were poorly reported.9 Additionally, the
efficacy of corticosteroids in patients with impaired kidney
functionwas not evaluated, and limited data exist for people
of Eastern or South-Asian origin.10-12 Global guidelines cur-
rently suggest a 6-month course of corticosteroids for indi-
vidualswithurinaryprotein excretionpersistently above 1 g/d
andanestimatedglomerular filtration rate (eGFR)greater than
50mL/min/1.73m2 after at least 3months of appropriate sup-
portive care. However, it is acknowledged that this weak rec-
ommendation is based on low-quality evidence.7
In addition, a recent trial of immunosuppression in IgA
nephropathy13 found that the addition of immunosuppres-
sion to intensive supportive care in 162 European partici-
pants reducedproteinuria but didnot reduce the rate of eGFR
decline over 3 years. As a result, it remains uncertainwhether
corticosteroid therapy isbeneficial in IgAnephropathyandhow
any benefits might trade off against potential risks.
The present study was designed to test the efficacy and
safety of full-dose corticosteroid therapy in preventing clini-
cally important kidney outcomes in patients with high-risk
IgA nephropathy.
Methods
Study Design and Patients
The Therapeutic Evaluation of Steroids in IgA Nephropathy
Global (TESTING) study was an investigator-initiated, multi-
center, double-blind, randomized clinical trial comparingoral
methylprednisolone with placebo on the risk of important
kidneyoutcomes inpeoplewith IgAnephropathy receivingap-
propriate supportive therapy, including blood pressure con-
trol and RAS blockade.
The study was overseen by a management committee,
coordinated by an academic research organization (The
George Institute for Global Health), and designed to be con-
ducted in up to 100 centers from China, Australia, India,
Canada, and Malaysia. Ethical approval to conduct the trial
was obtained from Peking University, the University of Syd-
ney, and the ethics committees of each study center; all par-
ticipants provided written informed consent. The study pro-
tocol is available in Supplement 1.
Eligibility required a diagnosis of primary IgA nephropa-
thy proven on kidney biopsy, an eGFR between 20 and
120 mL/min/1.73 m2 (calculated using the Chronic Kidney
Disease Epidemiology Collaboration creatinine equation14),
and urinary protein excretion greater than 1 g/d. Exclusion
criteria included a strong indication, or contraindication, for
corticosteroid therapy, based on the judgement of the treat-
ing physician (patients were included if the patient and phy-
sician had clinical equipoise regarding the use of the treat-
ment), or the use of systemic immunosuppressive therapy
in the previous year.
The full inclusionandexclusion criteria aredetailed in the
eTable 1 in Supplement 2.Given theplannedmultinational re-
cruitment andpotential for differences in response by ethnic-
ity, self-reported racial originbypatientswas collectedand re-
cordedby the investigators, basedonprespecified categories.
Randomization andMasking
Patients who were adherent to treatment and who had per-
sistent proteinuria greater than 1 g/d during the run-in period
were randomly assigned 1:1 via a password-protected en-
cryptedwebsite interface to receive oralmethylprednisolone
or matching placebo, stratified by region; proteinuria (<3 g/d
or≥3g/d); eGFR (<50mL/min/1.73m2or≥50mL/min/1.73m2);
and kidney biopsy findings (endocapillary proliferation sta-
tus [E1 or E0] according to the Oxford classification).15 Ran-
domization was performed using a minimization algorithm
based on the stratification variables; the algorithm was cen-
trally generated and used by all centers to minimize any im-
balances inkeyvariables. Patients, investigators, site staff, and
sponsors weremasked to treatment assignment for the dura-
tion of the study.
Procedures
Potentially eligible participants entered a run-in period from
4 to 12 weeks, during which treatment was adjusted to en-
sure that they were receiving the maximum labeled or toler-
ated dose of RAS blockade, along with optimized blood pres-
sure control according to Kidney Disease: Improving Global
Outcomes (KDIGO) guidelines for glomerulonephritis andhy-
pertension, for at least 3monthsprior to randomization. Study
Key Points
Question Do corticosteroids safely prevent loss of kidney
function in patients with IgA nephropathy receiving optimal
supportive therapy?
Findings This randomized clinical trial that included 262
participants was stopped early (after 28 of the 335 planned
events) due to a significantly increased risk of serious adverse
events with oral methylprednisolone vs placebo (14.7% vs 3.2%,
primarily excess infections); at that point, the primary efficacy
outcome favoredmethylprednisolone (5.9% vs 15.9%).
Meaning Oral corticosteroid therapy was associated with an
increased risk of serious adverse events; the effect on kidney
outcomes remains uncertain due to the limited number of events.
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treatment consistedof0.6 to0.8mg/kg/d of oralmethylpred-
nisoloneormatchingplacebo (roundedto thenearest4mgand
with a maximal dose of 48 mg/d) for 2 months, then tapered
by 8 mg/d each month, with a total treatment period of 6 to
8 months.
Participants were followed up at regular intervals, for a
plannedmeanofat least 5years. Studyvisitsoccurredmonthly
for 3 months after randomization, then every 3 months until
month 12, and every 12months until the end of the study. Ad-
ditional telephone or face-to-face (at the choice of the inves-
tigator) visits were required at 3-month intervals to ascertain
kidney end points or adverse events.
Laboratory evaluation of all specimenswas performed in
a national central laboratory in China and at local laborato-
ries in other countries. Serum creatinine levels were mea-
suredusingenzymatic or Jaffemethodswith calibration trace-
able to isotope dilution mass spectrometry.
End Points
The primary composite end point was initially defined as the
first occurrence of a 50%decrease in eGFR, the development
of ESKD (defined as a need for maintenance dialysis or kid-
ney transplantation and adjudicated by a blinded, indepen-
dentcommittee),ordeathdue tokidneydisease.Basedoncon-
sensus recommendations from aworkshop sponsored by the
National Kidney Foundation and the US Food and Drug Ad-
ministration on renal end points,16,17 the steering committee
decided tomodify the creatinine-based component of thepri-
mary endpoint to a40%decrease in eGFR inNovember 2014,
prior to knowledge of any results, while other components of
the primary end point remained unchanged.
Secondary end points included the composite of ESKD,
40% decrease in eGFR, and all-cause death; the composite
of ESKD, 50% decrease in eGFR, and all-cause death; and
each of ESKD, death due to kidney disease, and all-cause
death. The secondary end points also included proteinuria
reduction evaluated by time-averaged proteinuria and eGFR
slope across all postrandomization study visits. Prespecified
exploratory end points included (1) a 25% decrease in eGFR
assessed separately or as part of a composite with ESKD and
all-cause death; (2) annual slope in the inverse of serum cre-
atinine level; (3) proteinuria remission at months 6, 12, and
24; and (4) disappearance of hematuria at last follow-up.
A statistical analysis plan (Supplement 3) was developed by
a subgroup of the steering committee, blinded to any infor-
mation about study outcomes.
Adverse Events and Safety
Predefined safety outcomeswere all-causemortality, total se-
rious adverse events, serious infections, new diabetes, gas-
trointestinal hemorrhage, fracture or osteonecrosis, and car-
diovascularevents.Seriousadverseevents (SAEs)weredefined
according to the International Conference on Harmonization
Guideline for Clinical Safety Data Management.
Interim Analyses and DataMonitoring
Anindependentdataandsafetymonitoringcommittee (DSMC)
met twice yearly to review efficacy and safety data; 2 formal
interim efficacy analyses were planned when one-third and
two-thirdsof theprimaryendpointshadoccurred,using stop-
ping boundaries defined using the O’Brien Fleming method,
while the decisions about stopping for harm were not based
on predefined statistical rules. The DSMC could recommend
terminating the study early if there was clear and substantial
evidence of benefit or if the risk of adverse events was deter-
mined to likely substantially outweigh the potential benefits
(Supplement 4).
Statistical Analysis
The initial sample-size calculations assumed an annual com-
bined event rate for the primary end point (50% eGFR de-
crease, ESKD, and death due to kidney disease) of 7%, requir-
ing 1300 participants to detect a 30% relative risk reduction
in theprimary endpointwith90%power (α = .05). A 30%risk
reductionwas selected because itwas the upper boundof the
95% confidence interval in a meta-analysis of previous trials
assessing steroids for IgAnephropathy.9After theprimaryend
point was modified to include a 40% reduction in eGFR, the
estimated annual event rate increased to 12% based on data
from a large Chinese cohort18 and a previous trial,10 and the
required sample size was reduced to 750 participants to pro-
videmore than90%power todetect a 30%risk reductionwith
methylprednisolone. The trial was event-driven throughout,
with a total of 335 primary outcomes expected over a mean
follow-up of 5 years.
All analyses were conducted according to the intention-
to-treat principle. The effect of treatment on the primary
composite end point was estimated using an unadjusted Cox
proportional hazards model. The proportionality assumption
was assessed by plotting log{−log[S(t)]} and assessing
whether the curves were parallel and with a test of interac-
tion between time and treatment in the Cox model. Data for
patients were censored at the date of death or the date of data
extraction for those still alive. Because of small numbers,
other composite end points as well as the individual compo-
nents were summarized as the proportions of patients with at
least 1 event and compared using Fisher exact test. Confi-
dence intervals for risk differences were calculated using the
Newcombe score method.
Theyearly rateof eGFRdeclinewascalculatedas themean
of the individual slopesobtained fromindividual linear regres-
sions of eGFR over time. Time-averaged proteinuria was cal-
culated as the weighted mean of all postrandomization mea-
surements,withweightsrepresentingthetimeelapsedsincethe
previous measurement. Mean eGFR slopes and mean time-
averagedproteinuria valueswere compared across treatments
using t tests. Overall differences in eGFR and proteinuria over
time were estimated using linear mixed models including all
postrandomizationmeasurements.Fixedeffects includedbase-
linemeasurement,month (as a categorical variablewith 5 cat-
egories), treatment group, and the interaction betweenmonth
and treatment group. A random intercept by participant was
used to model within-participant correlations. Complete re-
mission of proteinuria was defined as achievement of urinary
protein level less than 200mg/d, andpartial remission as 50%
or greater proteinuria reductions, with achieved urine protein
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less than 1g/d.Details on theanalysisof exploratoryendpoints
are included in the statistical analysis plan (Supplement 3).
All P valueswere 2-sided, and P values less than .05were
considered to indicate statistical significance. Formal adjust-
ment formultiple comparisonswasnot performed, but analy-
ses were interpreted conservatively in light of the number of
outcomesassessed, andeffectsonsecondaryoutcomesshould
be considered exploratory.
The homogeneity of the treatment effects on the primary
outcome across specified subgroupswas tested by adding in-
teraction terms to the Cox models, with predefined sub-
groups including proteinuria (<3.0 vs ≥3.0 g/d), eGFR (<50 vs
≥50 mL/min/1.73 m2), endocapillary hypercellularity on his-
tological scoring (yes or no), and baseline maximum toler-
ated dose of RAS blockade (>80%, 50%-80%, and <50%
achieved of maximum labeled dose). All analyses were per-
formed using SAS version 9.4 (SAS Institute).
Results
Between May 2012 and November 2015, 523 potentially eli-
gible patients were screened, of whom 262 (48.8%) were eli-
gible and underwent randomization (136 to methylpredniso-
lone, 126 to placebo) (Figure 1). Recruitment was stopped
early, and study treatment discontinued among randomized
participants, owing to an excess of SAEs (mostly infections)
in the corticosteroid group, based on advice from the DSMC
at a regularly scheduled meeting in November 2015 that con-
cluded that the trial should not continue in its current form;
the full recommendations of the DSMC are reported in
Supplement 5. The steering committee accepted this advice
and decided to terminate the study intervention on this basis
on November 13, 2015.
After termination of study intervention, patients still re-
ceiving study drugwere unblinded and those receivingmeth-
ylprednisolone were asked to return for a safety-assessment
visit;allparticipantswereaskedtoreturnforanadditionalstudy
visit at which updated informed consent for ongoing data col-
lection, and additional information regarding study out-
comes,was obtained. After termination, the studybegan tran-
sitioningfromthetreatmentphasetocontinuingfollow-upwhile
participants were no longer receiving randomized therapy; a
transitional analysis was conducted and is reported here.
Participantswere recruited fromChinaandAustralia.Cen-
ters in India, Canada, and Malaysia joined the study later be-
cause of funding timing and were preparing to enroll partici-
pantswhenrecruitmentwasstopped,butnopatientshadbeen
recruited to the trial from these countries.
The 2 randomized groups had similar characteristics at
baseline (Table 1; eTable2 inSupplement2).Overall,meanage
was38.6 (SD, 11.1) years, 96women (37%)wereenrolled,mean
eGFR overall was 59.4 (25.0) mL/min/1.73 m2, and 24-hour
urineproteinexcretionwas2.40 (1.94) g/d.Bloodpressure lev-
els at entry were well controlled and similar in the 2 groups
during follow-up (eFigure 1 inSupplement2).Themedian time
between biopsy and randomization was 139 days (interquar-
tile range [IQR], 107-244 days).
At the time of this transitional analysis, participants had
been in the study for a median of 25 months (range, 5.7-45.3
months). A total of 226 (86%) had completed study treat-
ment andwere in the follow-upphase at the time the steering
committeemade thedecision todiscontinue recruitment and
study therapy.
Twenty-eight SAEs were reported in 20 participants
(14.7%) in the methylprednisolone group compared with 4
SAEs in 4 (3.2%) in the placebo group (relative risk, 4.63
[95% CI, 1.63 to 13.2]; P = .001 by Fisher exact test) (Table 2
and Figure 2), equating to a risk difference of 11.5% (95% CI,
4.8% to 18.2%). Most adverse events occurred in the first 3
months of treatment. This was mainly driven by an excess of
serious infections (2 fatal) among 11 patients (8.1%) in the
methylprednisolone group, compared with no serious infec-
tions in the placebo group (risk difference, 8.1% [95% CI,
3.5% to 13.9%]; P < .001). One patient in the placebo group
died of stroke after commencing dialysis. Effects on SAE
rates were broadly consistent according to predefined base-
line subgroups (eFigure 2A in Supplement 2), but small
event numbers limited subgroup power.
The primary composite renal outcome occurred in 8 par-
ticipants (5.9%) in the methylprednisolone group and 20
(15.9%) in the placebo group (hazard ratio, 0.37 [95% CI, 0.17
to0.85];P = .02; riskdifference, 10.0%[95%CI,2.5%to17.9%])
(Figure 3), including 4 (2.9%) and 10 (7.9%) participants,
Figure 1. Enrollment, Randomization, andFollow-upof StudyParticipants
523 Patients screeneda
261 Excluded during run-in phase
128 Proteinuria <1 g/d
3 Hepatitis B surface antigen
positive
25 Other
74 Participant decision
31 eGFR <20 or >120 mL/
min/1.73 m2
262 Randomized
136 Randomized to receive
methylprednisolone
134 Received methylprednisolone
as randomized
2 Did not receive
methylprednisolone
1 Patient decision
1 Early cessation of study
126 Randomized to receive placebo
121 Received placebo as
randomized
5 Did not receive placebo
2 Patient decision
3 Early cessation of study
2 Lost to follow-upb 0 Lost to follow-up
134 Included in primary analysis 126 Included in primary analysis
eGFR indicates estimated glomerular filtration rate.
a Patients were prescreened by the local investigator for eligibility, and 523
patients signed consent and entered the run-in phase; prescreening data were
not collected.
bOne participant moved overseas and could not be contacted; a second could
not be contacted despite many attempts.
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respectively, reaching ESKD (P = .10). A prespecified sub-
group analysis did not show evidence of significant differ-
ences in the effects of methylprednisolone on the composite
kidney failure outcome in subgroupsdefinedbybaseline pro-
teinuria (<3.0 vs ≥3.0 g/d), kidney function (eGFR <50 vs
≥50mL/min/1.73 m2), histological lesion scoring (E1 vs E0 by
Oxford classification), anddoseof angiotensin-converting en-
zyme inhibitors or angiotensin II receptorblockers (eFigure2B
in Supplement 2) but was limited by the small number of pri-
mary outcomes.
The effects on secondary outcomes are listed in Table 3.
Only 14 participants reached ESKD, with no clear difference
between the randomized groups. Of these participants, 7 had
a baseline eGFR less than 30 mL/min/1.73 m2, and another 4
had baseline eGFR between 30 and 50 mL/min/1.73 m2. The
effects onother components of theprimary outcomeweredi-
rectionally similar but not statistically significant. Partici-
pants randomized to corticosteroid therapy had a lower risk
of composite outcomes, includingESKD, all-cause death, and
either 25% (risk difference, 22.6% [95% CI, 12.1% to 32.6%];
Table 1. Baseline Characteristics of Participants
Characteristics
No. (%)
Methylprednisolone
(n = 136)
Placebo
(n = 126)
Age, mean (SD), ya 38.6 (11.5) 38.6 (10.7)
Women 50 (36.8) 46 (36.5)
Race
Chinese 130 (95.6) 121 (96.0)
White 5 (3.7) 3 (2.4)
Southeast Asian 1 (0.7) 2(1.6)
Smoker 34 (25.0) 31 (24.6)
Body mass indexb 24.4 (4.5) 23.4 (3.7)
Hypertension 71 (52.2) 52 (41.3)
Blood pressure, mean (SD), mm Hg
Systolic 123.9 (14.7) 124.3 (11.6)
Diastolic 79.3 (10.5) 79.8 (9.9)
Urine protein excretion, mean (SD), g/d 2.55 (2.45) 2.23 (1.11)
Urine red blood cells per HPF, median (range) 9.5 (2.0-32.0) 8.3 (3.0-26.0)
Microscopic hematuria 74 (62.2) 64 (62.1)
Serum creatinine, mean (SD), mg/dl 1.5 (0.6) 1.6 (0.6)
Estimated GFR, mean (SD), ml/min/1.73m2c 60.0 (24.8) 58.6 (25.2)
Estimated GFR category
≥50 mL/min/1.73m2 83 (61.5) 70 (56.9)
30-49 mL/min/1.73m2 41 (30.4) 38 (30.9)
<30 mL/min/1.73m2 11 (8.2) 15 (12.2)
Total cholesterol, mean (SD), mg/dl 188.9 (39.0) 191.8 (51.1)
Oxford histological scored
M1 76 (57.6) 75 (61.0)
E1 43 (31.6) 30 (23.8)
S1 94 (71.2) 89 (72.4)
T0 51 (38.6) 43 (35.0)
T1 58 (43.9) 60 (48.8)
T2 23 (17.4) 20 (16.3)
C0 54 (41.5) 57 (45.6)
C1 59 (45.4) 49 (39.2)
C2 17 (13.1) 19 (15.2)
Previous systematic corticosteroid therapy 5 (3.7) 3 (2.4)
Previous other immunosuppressant therapy 8 (5.9) 6 (4.8)
ACE inhibitors 83 (61.0) 76 (60.3)
ARBs 56 (41.2) 49 (38.9)
Dose of ACE inhibitor or ARB (% of maximum labeled dose)e
>80 66 (48.5) 57 (45.2)
50-80 58 (42.6) 52 (41.3)
<50 10 (7.4) 14 (11.1)
Dose not specified 2 (1.5) 3 (2.4)
Abbreviations: ACE,
angiotensin-converting enzyme;
ARB, angiotensin II receptor blocker;
GFR, glomerular filtration rate;
HPF, high-power field;
RAS, renin-angiotensin system.
a No patients younger than 18 years
were enrolled.
b Calculated as weight in kilograms
divided by height in meters
squared.
c Estimated with the use of the
Chronic Kidney Disease
Epidemiology Collaboration
creatinine equation.
dM1 indicates mesangial score >0.5;
E1, endocapillary hypercellularity
(any glomeruli); S1, segmental
glomerulosclerosis (any glomeruli);
T0, tubular atrophy/interstitial
fibrosis (<25% of cortical area);
T1, tubular atrophy/interstitial
fibrosis (25%-50% of cortical area);
T2, tubular atrophy/interstitial
fibrosis (>50% of cortical area);
C0, no crescents; C1, crescents
(<one-fourth of glomeruli);
C2, crescents (>one-fourth of
glomeruli). All patients had
endothelial score available; 132 in
themethylprednisolone group and
123 in the placebo group had
mesangial hypercellularity,
segmental glomerulosclerosis, and
tubular atrophy/interstitial fibrosis
lesion scores available. For the
crescent lesions, data were not
available for 7 patients.
e Patients receiving the specified
proportion of themaximum labeled
dose according to the product
information.
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P < .001)or40%(riskdifference,8.5%[95%CI,0.7%to16.6%];
P = .03) reductions in eGFR, but not composite outcomes in-
cluding a 50% reduction in eGFR (P = .29).
Themean annual rate of eGFRdecline in themethylpred-
nisolone group was −1.79 mL/min/1.73 m2, compared with
−6.95 mL/min/1.73 m2 in the placebo group (difference, 5.15
Figure 2. Time FromRandomization to First Serious Adverse Event, by Treatment Group
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Median at-risk duration of follow-up
was 19.7 (interquartile range,
9.2-30.1) months for
methylprednisolone and 25.2
(interquartile range, 14.8-32.7)
months for placebo. Relative risk,
4.63 (95% CI, 1.63-13.2); P = .001 by
Fisher exact test. SAE indicates
serious adverse event.
Table 2. Serious Adverse Events and Adverse Events of Special Interest by Treatment Group
Outcome
Methylprednisolone
(n = 136)
Placebo
(n = 126)
P ValueaPatients Events Patients Events
Total SAEsb 20 28 4 4 .001
SAEs of infectionc 11 13 0 0 <.001
Respiratory infection 4 0
Pneumoncystis pneumonia 3 0
Cryptococcal meningitis 1 0
Nocardia infection of skin and knee joint 1 0
Perianal abscess 1 0
Urinary tract infection 1 0
Fever 1 0
Gastrointestinal SAEsd 4 4 1 1 .62
Duodenal ulcer 1 0
Gastrointestinal bleeding 2 0
Gastric perforation 1 1
SAEs of bone disorders 3 3 0 0
Avascular necrosise 2 0 .12
Osteochondroma 1 0
Other SAEsf 5 8 3 3 .22
Pulmonary embolism 1 0
Deep vein thrombosis 2 0
Hepatotoxicity 1 0
Hemoptysis 1 0
Acute right upper quadrant pain 1 0
Arthralgia 1 0
Symptomatic incarcerated paraumbilical hernia 0 1
Uremia 0 2
Soft tissue injury 1 0
Adverse events of special interest 4 4 3 3
New-onset diabetes mellitus 2 3 .67
Avascular necrosise 1 0
Fracturee 1 0
Abbreviation: SAE, serious adverse
event.
a Comparison of proportion of
patients with at least 1 event using
Fisher exact test.
b Five patients hadmore than 1 SAE.
c Two patients hadmore than 1 SAE of
infection.
dOne patient had 1 gastrointestinal,
1 infection, and 1 other SAE.
e Two patients with avascular
necrosis were reported as having
SAEs; 1 patient with avascular
necrosis and 1 with fracture were
reported as having adverse events
of special interest. P values obtained
by combining these events.
f One patient had 4 other SAEs.
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[95% CI, 0.42 to 9.89] mL/min/1.73 m2; P = .03). A prespeci-
fied sensitivity analysis excluding the treatment period with
highest corticosteroid exposure (from month 1 to 3, −0.11 vs
−6.38 mL/min/1.73 m2; risk difference, 6.27 [95% CI,
2.77 to 9.76] mL/min/1.73 m2; P < .001) and the entire treat-
ment exposure period (from month 1 to 6, −1.64 vs
−5.64 mL/min/1.73 m2; risk difference, 4.00 [95% CI, 1.22 to
6.78]mL/min/1.73m2;P = .005) showedsimilar results.Analy-
ses using annual change of inverse of serum creatinine level
instead of eGFR showed similar results. The eGFR in the cor-
ticosteroid-treated group increased early and remained sig-
nificantly higher than in the placebo-treated group at each
studyvisit, to3yearsof follow-up(Figure4A).Theoverallmean
difference (methylprednisolone − placebo) in eGFR over the
entire follow-up (months 3-36) was 6.1 mL/min/1.73 m2 (95%
CI, 2.9 to 9.3; P < .001).
Mean proteinuria during follow-up was significantly re-
duced in themethylprednisolone-treatedgroup (1.37 [SD, 1.08]
vs 2.36 (SD, 1.67) g/d; difference, −0.99 g/d [95% CI, −1.34 to
−0.64g/d];P < .001) (Figure4B). Thiswas consistentwith the
overall difference estimatedwith linearmixedmodels (differ-
ence, −1.0 g/d [95%CI, −1.36 to −0.65]; P < .001). The propor-
tionof individuals achieving either complete or partial remis-
sionofproteinuria at 6monthswas45.1% in the corticosteroid
groupvs13.7%intheplacebogroup(riskdifference,31.4%[95%
CI, 18.9%to42.5%];P < .001),with similar results at 12months
(52.2% vs 13.6%; risk difference, 38.5% [95% CI, 25.2% to
50.0%];P < .001) and 24months (48.2%vs 21.8%; risk differ-
ence, 26.4% [95%CI, 8.7% to 42.0%]; P = .005). At 6months,
the rates of complete remission of proteinuria were 7.8% for
the corticosteroidgroupvs 1.1% for theplacebogroup (riskdif-
ference, 6.8% [95%CI, 0.8% to 13.6%]; P = .04) and of partial
remissionwere45.1%vs 13.7% (riskdifference, 31.4% [95%CI,
18.9% to42.5%];P < .001).Microscopichematuria (definedas
at least 5 redbloodcells perhigh-power field)wasnoted in 138
patients (62.2%) at baseline. Among those, 127 had at least 1
subsequent measurement, with 61 (48.0%) showing remis-
sion by the last visit. This occurred in 58.8%of participants in
themethylprednisolone group vs 35.6% in the placebo group
(risk difference, 23.2% [95% CI, 5.8% to 38.7%]; P = .01).
Discussion
This study assessed a full-dose corticosteroid regimen in pa-
tients with IgA nephropathy at high risk and found high rates
of serious adverse outcomes due mainly to an increased risk
of serious infections, resulting in theearly cessationof recruit-
ment to the trial.While proteinuria and eGFR levels were im-
proved, and suggestions of potential benefit for the primary
outcome were observed, there were too few primary out-
comes to draw definitive conclusions about treatment effi-
cacy from this trial.
The nearly 5 times higher risk of SAEs is a particularly im-
portant finding, given thatmanyprevious corticosteroid trials
in IgA nephropathy have collected and reported adverse ef-
fects inconsistently.9 It is possible that the high rate of infec-
tions was related to the trial population or the specific treat-
ment regimen used in this study; however, the Supportive
Versus ImmunosuppressiveTherapy for theTreatmentofPro-
gressive IgANephropathy (STOP-IgAN) trial also collectedand
reporteddetailed adverse-eventdata and foundsimilarlyhigh
ratesofsevere infectionsamongthe immunosuppressiongroup
(8.1% vs 9.8%), including 1 death in the combination immu-
nosuppression group.13 The excess of SAEs (mostly infec-
tions) observed in this study has implications for clinical de-
cision making and treatment guidelines for the use of
corticosteroids in IgA nephropathy. Future studies could also
consider theuse of prophylactic antibiotic therapy,whichhas
not been used in any of the completed studies and is not rec-
ommended in clinical practice guidelines.
While interpretation of the primary results is limited, the
findings are consistentwith ameta-analysis of 9 smaller trials,
which found that corticosteroid therapy was associated with
a lower risk of composite renal outcomes (50% reduction in
eGFR or ESKD; relative risk, 0.32 [95% CI, 0.15 to 0.67]).19
Figure 3. Time FromRandomization to First Primary Composite Outcome of 40%eGFRDecrease, ESKD,
or Death Due to Kidney Failure, by Treatment Group
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These findings contrast with those from the STOP-IgAN
study,which randomized 162participants to immunosuppres-
sionor supportive therapyalone for3years and foundnoeffect
onslopeofeGFRdeclineorESKD.13Possible reasons for thedif-
ference inresults includethefact thatparticipants inthepresent
trialwereathigherriskbecauseofhighermeanbaselineprotein-
uria levelsandperhapsalsobecause individualsofEasternAsian
origin (eg, China, Japan, Philippines, and Vietnam) may have
more rapid ratesof eGFRdeclineandkidney failure.20The rate
of eGFR loss among patients in the supportive-therapy group
of this study was higher than that in STOP-IgAN (−6.95 vs
−1.6mL/min/1.73m2peryear),makingdetectionof anybenefit
more likely.Theannual rateof eGFRdecline inSTOP-IgANwas
also lower than that observed in a cohort study21 and a recent
trial,22 both fromEurope.The longerperiodofRASblockade in
STOP-IgANisanotherdifference;however, therateofeGFRloss
in the placebo group did not slow appreciablywith longer RAS
exposure timeduring follow-up in theTESTINGplacebogroup,
andtheeffectsdidnotdifferbydoseofRASblockade.Although
ethnic differences in response to treatment are possible, this is
not suggested by the results of previous trials.9 The shorter
follow-upof thepresent trial comparedwiththeSTOPIgANtrial
Table 3. Effects of Corticosteroids on Prespecified Primary and Secondary Outcomes
Outcome
Methylprednisolone
(n = 136)
Placebo
(n = 126)
Absolute Difference
(95%CI) P Valuea
Primary outcome, No. (%)
40% eGFR decrease, ESKD, or death
due to kidney failure
8 (5.9) 20 (15.9) 10.0 (2.5 to 17.9) .02
Protocol-specified secondary outcomes
40% eGFR decrease, ESKD, or all-cause death,
No. (%)
10 (7.4) 20 (15.9) 8.5 (0.7 to 16.6) .03
50% eGFR decrease, ESKD, or all-cause death,
No. (%)
10 (7.4) 15 (11.9) 4.6 (2.7 to 12.1) .29
40% eGFR decrease, No. (%) 7 (5.1) 16 (12.7) 7.6 (0.6 to 15.0) .05
50% eGFR decrease, No. (%) 7 (5.1) 11 (8.7) 3.6 (2.8 to 10.3) .33
ESKD or death due to kidney failure, No. (%)b 4 (2.9) 10 (7.9) 5.0 (0.7 to 11.3) .10
Death due to any cause, No. (%) 2 (1.5) 1 (0.8) 0.7 (−0.3 to 0.4 to) >.99
Rate of eGFR decline using all visits,
mean (95% CI), mL/min/1.73 m2c
−1.79 (−4.74 to 1.16) −6.95 (−10.68 to −3.21) 5.15(0.42 to 9.89) .03
Rate of eGFR decline excluding values
on high-exposure treatment,
mean (95% CI), mL/min/1.73 m2d
−0.11 (−2.52 to 2.30) −6.38 (−8.93 to −3.82) 6.27 (2.77 to 9.76) <.001
Rate of eGFR decline excluding values on treatment,
mean (95% CI), mL/min/1.73 m2b,e
−1.64 (−3.33 to 0.05) −5.64 (−7.86 to −3.41) 4.00 (1.22 to 6.78) .005
Time-averaged proteinuria, mean (95% CI), g/d 1.37 (1.18 to 1.56) 2.36 (2.06 to 2.66) −0.99 (−1.34 to −0.64) <.001
Prespecified exploratory outcomes
25% eGFR decrease, ESKD, or all cause death,
No. (%)
20 (14.7) 47 (37.3) 22.6 (12.1 to 32.6) <.001
25% eGFR decrease, No. (%) 17 (12.5) 44 (34.9) 22.4 (12.2 − 32.2) <.001
Yearly decline in 1/creatinine using all visits,
mean (95% CI), mg/dLf
−0.03 (−0.07 to 0.01) −0.07 (−0.11 to −0.03) 0.04 (−0.01 to 0.10) .16
Yearly decline in 1/creatinine excluding values
on high-exposure treatment, mean (95% CI), mg/dLg
−0.00 (−0.03 to 0.02) −0.07 (−0.10 to −0.04) 0.06 (0.02 to 0.11) .002
Yearly decline in 1/creatinine excluding values
on treatment, mean (95% CI), mg/dLh
−0.01 (−0.04 to 0.01) −0.06 (−0.08 to −0.04) 0.04 (0.01 to 0.07 .003
Total proteinuria remission, No./total (%)i
Month 6 46/102 (45.1) 13/95 (13.7) 31.4 (18.9 to 42.5) <.001
Month 12 48/92 (52.2) 12/88 (13.6) 38.5 (25.2 to 50.0) <.001
Month 24 27/56 (48.2) 12/55 (21.8) 26.4 (8.7 to 42.0) .005
Disappearance of hematuria at last visit,
No./total (%)j
40/68 (58.8) 21/59 (35.6) 23.2 (5.8 to 38.7) .01
Abbreviations: eGFR, estimated glomerular filtration rate; ESKD, end-stage
kidney disease.
a P value for primary outcome calculated using survival analysis. Other P values
calculated using t tests or Fisher exact tests.
bNo deaths due to kidney failure were observed in the trial.
c Defined for each individual patient using the slope from least-squares linear
regression of all eGFR estimates over time.
dDefined as above, but excluding the treatment period with highest
corticosteroid exposure frommonth 1 andmonth 3.
e Defined as above, but excluding the treatment period with highest
corticosteroid exposure frommonths 1, 3, and 6.
f Defined for each individual patient using the slope from least-squares linear
regression of all reciprocal of serum creatinine values over time.
g Defined as above but excluding the treatment period with highest
corticosteroid exposure frommonth 1 andmonth 3.
hDefined as above but excluding the treatment period with corticosteroid
exposure frommonths 1, 3, and 6.
i Total proteinuria remission is defined as complete or partial remission.
Complete proteinuria remission is defined as 24-hour urinary protein less than
200mg/d and partial proteinuria remission as proteinuria less than 50% of
baseline by 24-hour urinary protein and less than 1 g/d.
j Defined as urinalysis revealing less than 5 red blood cells per high-power field
at the end of the study or last available visit for those participants with
microhematuria or macrohematuria at randomization visit.
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is anotherpossible reason.Ongoing follow-upofbothstudies is
important to better define the longer-termkidney effects, par-
ticularly as the adverse eventsmostly occurred early, whereas
the benefits appeared to accrue throughout follow-up.
Theearly increase in eGFRobserved in the corticosteroid-
treatedparticipants raises thepossibility that someof theeGFR
effectsmaybedue to sarcopenic effects of corticosteroid lead-
ing to reduced creatinine generation (eFigure 3 in Supplement
2) or due to corticosteroid-induced hyperfiltration.23,24 Ex-
cluding the creatinine measures during the treatment period
attenuated the difference in the rate of eGFR loss over time,
but it remained significantly lower in the corticosteroid-
treated group. The early reduction in proteinuria, as well as
the difference in rates of the more clinically important pri-
mary outcome, suggest that potentially clinically important
benefits are possible,whichwill be further clarifiedby theon-
going follow-up of study participants.
Strengthsofthis trial includetherelatively largesamplesize.
Theongoingparticipant follow-upwill help tomoreaccurately
assess theefficacyofcorticosteroids.This studyalsohasseveral
limitations. Although to our knowledge this is the largest trial
reported todateamongpatientswith IgAnephropathy, recruit-
ment was stopped earlier than planned because of excess
adverse events, so power was less than predicted, and both
risks and benefits might be overestimated as a result. Most
participantswereofasingleethnicity,meaningethnicity-based
treatment responses cannot be assessed. The reliance on
eGFR based on serum creatinine measurement is another
limitation,particularlybecausecorticosteroidsmayreducecre-
atinine generation.
Conclusions
Amongpatientswith IgAnephropathyandproteinuria greater
than 1 g/d, oralmethylprednisolonewasassociatedwithan in-
creased riskof seriousadverseevents, primarily infections.Al-
though the results are consistent with potential benefit, de-
finitive conclusions about treatment benefit cannot bemade,
owing to early termination of the trial.
Figure 4. Effect ofMethylprednisolone Therapy on eGFR and Proteinuria During Follow-up
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Randomization proteinuria and
estimated glomerular filtration rate
(eGFR) data are not available for 4
participants who were therefore
excluded from this analysis. Error
bars indicate 95% confidence
intervals. A, Mean difference in eGFR
was 5.14 (95% CI, 1.90 to 8.37)
mL/min/1.73 m2 at month 3;
6.74 (95% CI, 3.40 to 10.09)
mL/min/1.73 m2 at month 6; 4.62
(95% CI, 1.16 to 8.09) mL/min/1.73 m2
at month 12; 5.43 (95% CI, 1.37 to
9.48) mL/min/1.73 m2 at month 24;
and 7.67 (95% CI, 1.91 to 13.43)
mL/min/1.73 m2 at month 36 (P < .01
for all). The annual rate of eGFR
decline was lower in the
methylprednisolone group (−1.79 vs
−6.95mL/min/1.73 m2 per year; mean
difference, 5.15 [95% CI, 0.42 to
9.89]; P = .03). B, Mean difference in
proteinuria was −0.83 (95% CI, −1.18
to −0.47) g/d at month 3; −1.00 (95%
CI, −1.37 to −0.63) g/d at month 6;
−1.20 (95% CI, −1.59 to −0.81) g/d at
month 12; −1.03 (95% CI, −1.49 to
−0.56) g/d at month 24; and −0.93
(95% CI, −1.60 to −0.25) g/d at
month 36 (P < .01 for all).
Time-averaged proteinuria was
significantly lower in the
methylprednisolone group than in
the placebo group (1.37 vs 2.36 g/d;
mean difference, −0.99 [95% CI,
−1.34 to −0.64]; P < .001).
Research Original Investigation Oral Methylprednisolone and Clinical Outcomes in IgA Nephropathy
440 JAMA August 1, 2017 Volume 318, Number 5 (Reprinted) jama.com
© 2017 American Medical Association. All rights reserved.
ARTICLE INFORMATION
Accepted for Publication: June 29, 2017.
Author Affiliations: Renal Division, Department of
Medicine, Peking University First Hospital, Beijing,
China (Lv, Zhang, Zhao, Wang); The George
Institute for Global Health, University of New South
Wales, Sydney, Australia (Lv, Wong, Jardine,
Monaghan, Woodward, Billot, Cass, Perkovic);
Sunnybrook Health Sciences Centre, Toronto,
Ontario, Canada (Hladunewich); The George
Institute for Global Health, New Delhi, India (Jha);
University of Oxford, Oxford, United Kingdom
(Jha); The University of British Columbia,
Vancouver, British Columbia, Canada
(Barbour, Levin); University Health Network,
Toronto, Ontario, Canada (Reich, Cattran);
David Geffen School of Medicine, University of
California-Los Angeles (Glassock); Royal Free and
University College Medical School, London,
United Kingdom (Wheeler); The George Institute
for Global Health, University of Oxford, Oxford,
United Kingdom (Woodward); Department of
Epidemiology, Johns Hopkins University, Baltimore,
Maryland (Woodward); University of Hong Kong,
Hong Kong, China (Chan); Research Institute of
Nephrology, Jinling Hospital, Nanjing, China (Liu);
Australasian Kidney Trials Network, University of
Queensland, Brisbane, Australia (Johnson);
Menzies School of Health Research, Charles Darwin
University, Darwin, Australia (Cass); University of
Leicester, Leicester, United Kingdom (Feehally);
Division of Nephrology and Clinical Immunology,
RWTH Aachen University, Aachen, Germany
(Floege); Mario Negri Institute for Pharmacological
Research and Clinical Research Centre for Rare
Diseases, Bergamo, Italy (Remuzzi); Peking
University Clinical Research Institute, Beijing, China
(Wu); Indiana University School of Medicine,
Indianapolis (Agarwal).
Author Contributions:Drs Perkovic and Zhang had
full access to all of the data in the study and take
responsibility for the integrity of the data and the
accuracy of the data analysis.
Concept and design: Lv, Zhang, Jardine, Monaghan,
Barbour, Reich, Cattran, Glassock, Levin, Wheeler,
Chan, Johnson, Cass, Feehally, Floege, Remuzzi,
Wu, Wang, Perkovic.
Acquisition, analysis, or interpretation of data: Lv,
Zhang, Wong, Jardine, Hladunewich, Jha, Zhao,
Barbour, Cattran, Glassock, Woodward, Billot, Chan,
Liu, Johnson, Aggarwal, Perkovic.
Drafting of the manuscript: Lv, Zhang, Wong,
Monaghan, Wheeler, Liu, Johnson, Wang, Perkovic.
Critical revision of the manuscript for important
intellectual content: Lv, Zhang, Wong, Jardine,
Hladunewich, Jha, Zhao, Barbour, Reich, Cattran,
Glassock, Levin, Wheeler, Woodward, Billot, Chan,
Johnson, Cass, Feehally, Floege, Remuzzi, Wu,
Aggarwal, Perkovic.
Statistical analysis:Woodward, Billot.
Obtained funding: Zhang, Hladunewich, Reich,
Cattran, Cass, Perkovic.
Administrative, technical, or material support: Lv,
Zhang, Wong, Jardine, Jha, Monaghan, Reich,
Cattran, Levin, Liu, Wu, Perkovic.
Supervision: Lv, Zhang, Wong, Jardine, Jha, Zhao,
Barbour, Glassock, Wheeler, Chan, Johnson, Cass,
Floege, Aggarwal, Wang, Perkovic.
Conflict of Interest Disclosures: All authors have
completed and submitted the ICMJE Form for
Disclosure of Potential Conflicts of Interest. Dr Lv
reported receiving grant funding from Pfizer.
Dr Zhang reported receiving grant funding from
Peking University Health Central Clinical Research
Project and Pfizer during the conduct of the study
and receiving personal fees for steering committee
membership from Janssen. DrWong reported
receiving grant funding from the Diabetes Australia
Research Trust and giving scientific presentation
supported by Astra Zeneca, Roche, and Amgen.
Dr Jardine reported receiving grant funding from
the National Health andMedical Research Council
of Australia and the National Heart Foundation,
Cardiovascular Research Network, Gambro, Amgen,
Eli Lilly, Merck, Rebecca L. Cooper Medical Research
Foundation grant and KHA Project grant; and
receiving fees from Boehringer Ingelheim,
Fresenius, and Amgen directed to clinical research
programs. Dr Hladunewich reported receiving
grants from the Canadian Institute of Health
Research. Dr Jha reported receiving grant funding
from Baxter Healthcare and GSK. Dr Barbour
reported receiving grants from the Canadian
Institute of Health Research. Dr Reich reported
receiving grants and personal fees from Amgen.
Dr Cattran reported receiving unrestricted research
funding from Genentech; grant funding from the
Canadian Institutes of Health; research funding and
personal support from the National Institute of
Diabetes and Digestive and Kidney Diseases;
personal funding for serving on scientific advisory
board from Chemocentryx, Omerus, Mallinckrodt;
and serving without compensation on the scientific
board of Nephcure. DrWoodward reported
receiving personal fees from Amgen. DrWheeler
reported receiving honoraria from Akebia, Astra
Zeneca, Amgen, Boehringer Ingelheim, Janssen,
and Vifor Fresenius Medical Care. Dr Johnson
reported receiving grant funding from Baxter
Healthcare, Fresenius Medical Care, and the
National Health andMedical Research Council of
Australia; and receiving personal fees from Baxter
Healthcare, Fresenius Medical Care, and Astra
Zeneca. Dr Floege reported consulting on IgA
nephropathy for Pharmalink, Omeros, and Chugai
and giving scientific presentations supported by
Amgen and Vifor. Dr Remuzzi reported receiving
personal fees from Janssen Research and
Development. Dr Agarwal reported receiving
personal fees from Janssen, Boehringer Ingelheim,
Relypsa, Opko, Astra Zeneca, Amgen, Sanofi,
Akebia, Bayer, and UpToDate. Dr Perkovic reported
consulting on IgA nephropathy for Pharmalink, Eli
Lilly, and Novartis; giving scientific presentations
supported by Pfizer; and having a policy of
honoraria being paid to his institution.
Group Information: TESTING Steering
Committee: Cochairs:Hong Zhang, Peking
University Institute of Nephrology, China; Vlado
Perkovic, The George Institute for Global Health,
Australia; Hai-YanWang, Peking University Institute
of Nephrology, China (deceased).Members:
Michelle Hladunewich, Sunnybrook Health Sciences
Centre, Canada; Vivek Jha, The George Institute for
Global Health, India; The Postgraduate Institute of
Medical Education and Research, India; Jicheng Lv,
Peking University and The George Institute for
Global Health, China; HelenMonaghan, The George
Institute for Global Health, Australia; Muh Geot
Wong, The George Institute for Global Health,
Australia; Sean Barbour, The University of British
Columbia, Vancouver, Canada; Alan Cass, The
George Institute for Global Health, Australia;
Menzies School of Health Research, Charles Darwin
University, Australia; Daniel Cattran, University
Health Network, Canada; Tak Mao Chan, University
of Hong Kong, China; John Feehally, University of
Leicester, United Kingdom; Jürgen Floege,
University of Aachen, Germany; Richard J. Glassock,
UCLA David Geffen School of Medicine,
Los Angeles, California; Meg Jardine, The George
Institute for Global Health, Australia; David
Johnson, Australasian Kidney Trials Network,
Australia; Adeera Levin, the University of British
Columbia, Canada; Zhihong Liu, Nanjing University
School of Medicine, China; Heather Reich,
University Health Network, Canada; Giuseppe
Remuzzi, Mario Negri Institute for Pharmacological
Research and Clinical Research Centre for Rare
Diseases, Italy; DavidWheeler, Royal Free and
University College Medical School, United Kingdom;
MarkWoodward, The George Institute for Global
Health, Australia, and Department of Epidemiology,
Johns Hopkins University, Baltimore, Maryland;
YangfengWu, Peking University, China; Minghui
Zhao, Peking University Institute of Nephrology,
China; Rajiv Agarwal, Indiana University School of
Medicine, Indianapolis.Data and Safety
Monitoring Committee:David Jayne (chair),
TomGreene, MikeWalsh, AngelaWang. End Point
Adjudication Committee: Rajiv Agarwal (chair),
Li Zuo, AmandaMather, AmandaWang.Global
Coordinating Centre:HelenMonaghan (project
manager), Rebecca Anderson, Jicheng Lv, Muh
GeotWong, Dominic Byrne (senior data manager),
Laurent Billot, Sandrine Stepien, Jayanthi Mysore
(statisticians), Hong Zhang, Vlado Perkovic.
Endorsement: Australasian Kidney Trials Network.
Study Sites: China: Jicheng Lv, Peking University
First Hospital; Zhangsuo Liu, The First Affiliated
Hospital of Zhengzhou University; Caili Wang, First
Affiliated Hospital of Inner Mongolia, Baotou
Medical College; Shuxia Fu, The Second Hospital of
Hebei Medical University; Jinghong Zhao, Xinqiao
Hospital, Third Military Medical University; Lihua
Wang, The Second Affiliated Hospital of Shanxi
Medical University; Zhaohui Ni, Renji Hospital,
Shanghai Jiaotong University School of Medicine;
Nan Chen, Ruijin Hospital, Shanghai Jiaotong
University, School of Medicine; Haitao Zhang,
Nanjing General Hospital of Nanjing Military
Command; Qiong Luo, Peking University Shenzhen
Hospital; Mei Wang, Peking University People’s
Hospital; RongWang, Provincial Hospital Affliated
to Shandong University; Peng Li , Yantai
Yuhuangding Hospital; Jianghua Chen, The First
Affiliated Hospital of Zhejiang University of
Medicine; Guangyan Cai, The Chinese PLA General
Hospital; Ping Fu, West China Hospital of Sichuan
University; Chun Zhang, Union Hospital, Tongji
Medical College, Huazhong University of Science
and Technology; Guisen Li, Sichuan Academy of
Medical Science and Sichuan Provincial People’s
Hospital; Detian Li, Shengjing Hospital of China
Medical University; Dongmei Xu, Qianfoshan
Hospital Affiliated to Shandong University; Guohua
Ding, Renmin Hospital, Wuhan University; Hongyu
Chen, Hangzhou Chinese Medicine Hospital; Zhao
Hu, Qilu Hospital of Shandong University; Zhiling
Guo, First Affiliated Hospital of Henan University of
Science and Technology; Fuming Lu, Huashan
Hospital, Affiliated to Fudan University; Aiping
Zhang, Jinan General Hospital of PLA; Beiyan Bao,
Oral Methylprednisolone and Clinical Outcomes in IgA Nephropathy Original Investigation Research
jama.com (Reprinted) JAMA August 1, 2017 Volume 318, Number 5 441
© 2017 American Medical Association. All rights reserved.
Ningbo Urinary Kidney Disease Hospital; Qiang He,
Zhejiang Provincial People's Hospital; YueWang,
Beijing University Third Hospital; Li Gong, Inner
Mongolia People’s Hospital; Ying Li, The Third
Hospital of Hebei Medical University; Bing Liu,
Henan Provincial People’s Hospital; Yipu Shen,
Beijing Anzhen Hospital affiliated to Beijing Capital
Medical University; Gang Xu, Tongji Hospital of
Huazhong University of Science and Technology;
Changying Xing, The First Affiliated Hospital with
Nanjing Medical University (Jiangsu Province
Hospital); Wei Shi, Guangdong Province People’s
Hospital; Xiaoxuan Zhang, Fourth Hospital
Affiliated to Jilin University (FAWGeneral Hospital);
HuaWu, Beijing Hospital; Hongli Lin, First Affiliated
Hospital of Dalian Medical University; Xueqing Yu,
First Affiliated Hospital, Sun Yat-Sen University.
Hong Kong: Samual Fung, Princess Margaret
Hospital. Australia:Mona Razavian, Concord
Repatriation General Hospital; Chen Au Peh, Royal
Adelaide Hospital, Kathy Nicholls, Royal Melbourne
Hospital; Bruce Cooper, Royal North Shore Hospital;
David Johnson, Princess Alexandra Hospital.
Funding/Support: This study was supported by the
National Health andMedical Research Council of
Australia, the Peking University Health Central
Clinical Research Project, and the Canadian
Institutes of Health Research. Study drug was
provided by Pfizer Pharmaceuticals.
Role of the Funder/Sponsor: The funders/sponsors
had no role in the design and conduct of the study;
collection,management, analysis, and interpretation
of the data; preparation, review, or approval of the
manuscript; and decision to submit themanuscript
for publication.
Additional Contributions:Hai-YanWang, MD,
is deceased.
REFERENCES
1. Wyatt RJ, Julian BA. IgA nephropathy.NEngl JMed.
2013;368(25):2402-2414.
2. LeW, Liang S, Hu Y, et al. Long-term renal
survival and related risk factors in patients with IgA
nephropathy: results from a cohort of 1155 cases in
a Chinese adult population.Nephrol Dial Transplant.
2012;27(4):1479-1485.
3. Reich HN, Troyanov S, Scholey JW, Cattran DC;
Toronto Glomerulonephritis Registry. Remission of
proteinuria improves prognosis in IgA nephropathy.
J Am Soc Nephrol. 2007;18(12):3177-3183.
4. Lv J, Zhang H, Zhou Y, Li G, ZouW,Wang H.
Natural history of immunoglobulin A nephropathy
and predictive factors of prognosis: a long-term
follow up of 204 cases in China.Nephrology (Carlton).
2008;13(3):242-246.
5. Coppo R, Peruzzi L, Amore A, et al. IgACE:
a placebo-controlled, randomized trial of
angiotensin-converting enzyme inhibitors in
children and young people with IgA nephropathy
andmoderate proteinuria. J Am Soc Nephrol. 2007;
18(6):1880-1888.
6. The GISEN Group (Gruppo Italiano di Studi
Epidemiologici in Nefrologia). Randomised
placebo-controlled trial of effect of ramipril on
decline in glomerular filtration rate and risk of
terminal renal failure in proteinuric, non-diabetic
nephropathy. Lancet. 1997;349(9069):1857-1863.
7. Cattran DC, Feehally J, Cook HT, et al. Kidney
disease: Improving Global Outcomes (KDIGO)
glomerulonephritis work group: KDIGO clinical
practice guideline for glomerulonephritis. Kidney Int
Suppl. 2012;2(2):139-274.
8. Floege J, AmannK. Primary glomerulonephritides.
Lancet. 2016;387(10032):2036-2048.
9. Lv J, Xu D, Perkovic V, et al; TESTING Study
Group. Corticosteroid therapy in IgA nephropathy.
J Am Soc Nephrol. 2012;23(6):1108-1116.
10. Manno C, Torres DD, Rossini M, Pesce F,
Schena FP. Randomized controlled clinical trial of
corticosteroids plus ACE-inhibitors with long-term
follow-up in proteinuric IgA nephropathy. Nephrol
Dial Transplant. 2009;24(12):3694-3701.
11. Lv J, Zhang H, Chen Y, et al. Combination
therapy of prednisone and ACE inhibitor versus
ACE-inhibitor therapy alone in patients with IgA
nephropathy: a randomized controlled trial. Am J
Kidney Dis. 2009;53(1):26-32.
12. Pozzi C, Bolasco PG, Fogazzi GB, et al.
Corticosteroids in IgA nephropathy: a randomised
controlled trial. Lancet. 1999;353(9156):883-887.
13. Rauen T, Eitner F, Fitzner C, et al; STOP-IgAN
Investigators. Intensive supportive care plus
immunosuppression in IgA nephropathy. N Engl J
Med. 2015;373(23):2225-2236.
14. Levey AS, Stevens LA, Schmid CH, et al;
CKD-EPI (Chronic Kidney Disease Epidemiology
Collaboration). A new equation to estimate
glomerular filtration rate. Ann Intern Med. 2009;
150(9):604-612.
15. Cattran DC, Coppo R, Cook HT, et al; Working
Group of the International IgA Nephropathy
Network and the Renal Pathology Society. The
Oxford classification of IgA nephropathy: rationale,
clinicopathological correlations, and classification.
Kidney Int. 2009;76(5):534-545.
16. Coresh J, Turin TC, Matsushita K, et al; CKD
Prognosis Consortium. Decline in estimated
glomerular filtration rate and subsequent risk of
end-stage renal disease andmortality. JAMA. 2014;
311(24):2518-2531.
17. Levey AS, Inker LA, Matsushita K, et al. GFR
decline as an end point for clinical trials in CKD:
a scientific workshop sponsored by the National
Kidney Foundation and the US Food and Drug
Administration.Am JKidneyDis. 2014;64(6):821-835.
18. Li X, Liu Y, Lv J, et al. Progression of IgA
nephropathy under current therapy regimen in a
Chinese population. Clin J Am Soc Nephrol. 2014;9
(3):484-489.
19. Inker LA, Mondal H, Greene T, et al. Early
change in urine protein as a surrogate end point in
studies of IgA nephropathy: an individual-patient
meta-analysis.Am J Kidney Dis. 2016;68(3):392-401.
20. Barbour SJ, Cattran DC, Kim SJ, et al.
Individuals of Pacific Asian origin with IgA
nephropathy have an increased risk of progression
to end-stage renal disease. Kidney Int. 2013;84(5):
1017-1024.
21. Tesar V, Troyanov S, Bellur S, et al.
Corticosteroids in IgA nephropathy: a retrospective
analysis from the VALIGA study. J Am Soc Nephrol.
2015;26(9):2248-2258.
22. Fellström BC, Barratt J, Cook H, et al; NEFIGAN
Trial Investigators. Targeted-release budesonide
versus placebo in patients with IgA nephropathy
(NEFIGAN): a double-blind, randomised,
placebo-controlled phase 2b trial. Lancet. 2017;389
(10084):2117-2127.
23. Connell JM,Whitworth JA, Davies DL, Lever AF,
Richards AM, Fraser R. Effects of ACTH and cortisol
administration on blood pressure, electrolyte
metabolism, atrial natriuretic peptide and renal
function in normal man. J Hypertens. 1987;5(4):
425-433.
24. Smets P, Meyer E, Maddens B, Daminet S.
Cushing’s syndrome, glucocorticoids and the
kidney. Gen Comp Endocrinol. 2010;169(1):1-10.
Research Original Investigation Oral Methylprednisolone and Clinical Outcomes in IgA Nephropathy
442 JAMA August 1, 2017 Volume 318, Number 5 (Reprinted) jama.com
© 2017 American Medical Association. All rights reserved.
